- •Diabetic Retinopathy
- •Preface
- •Contents
- •Contributors
- •Nonproliferative Diabetic Retinopathy
- •Nonproliferative Diabetic Retinopathy
- •Inflammatory Mechanisms
- •Microaneurysms
- •Vascular Permeability
- •Capillary Closure
- •Classification Of Nonproliferative Retinopathy
- •Macular Edema
- •Risk Factors For Progression Of Retinopathy
- •Severity of Retinopathy
- •Glycemic Control
- •The Diabetes Control and Complications Trial
- •Epidemiology of Diabetes Interventions and Complications Trial
- •The United Kingdom Prospective Diabetes Study
- •Hypertension
- •The United Kingdom Prospective Diabetes Study
- •Appropriate Blood Pressure Control in Diabetes Trials
- •Elevated Serum Lipid Levels
- •Pregnancy and Diabetic Retinopathy
- •Other Systemic Risk Factors
- •Management Of Nonproliferative Diabetic Retinopathy
- •Photocoagulation
- •Scatter Photocoagulation for Nonproliferative Diabetic Retinopathy
- •Scatter Photocoagulation for Proliferative Retinopathy
- •Focal Photocoagulation for Diabetic Macular Edema
- •Other Treatment of Diabetic Macular Edema
- •Medical Therapy
- •Aspirin And Antiplatelet Treatments
- •Aldose Reductase Inhibitors
- •Other Medical Treatments
- •Summary
- •Acknowledgment
- •References
- •Proliferative Diabetic Retinopathy
- •Development and Natural History
- •Histopathology and Early Development
- •Proliferation and Regression of New Vessels
- •Contraction of the Vitreous and Fibrovascular Proliferations
- •Retinal Distortion and Detachment
- •Burned-Out Proliferative Diabetic Retinopathy
- •Systemic Associations
- •Proliferative Diabetic Retinopathy and Glycemic Control
- •Other Risk Factors for Proliferative Diabetic Retinopathy
- •Rubeosis Iridis
- •Anterior Hyaloidal Fibrovascular Proliferation
- •Management of Proliferative Diabetic Retinopathy
- •Pituitary Ablation
- •Photocoagulation
- •Randomized Clinical Trials of Laser Photocoagulation
- •The Diabetic Retinopathy Study
- •Risks and Benefits Photocoagulation In The Drs
- •The Early Treatment Diabetic Retinopathy Study
- •Indications For Photocoagulation of Pdr
- •PRP and Macular Edema
- •PRP Treatment Techniques
- •Vitrectomy for PDR
- •Pharmacologic Treatment of PDR
- •Acknowledgment
- •References
- •Brief Historical Background
- •The Wesdr
- •Prevalence of Diabetic Retinopathy
- •Incidence of Diabetic Retinopathy
- •Diabetic Retinopathy in African American and Hispanic Whites
- •Native Americans and Asian Americans
- •Age and Puberty
- •Genetic and Familial Factors
- •Modifiable Risk Factors
- •Hyperglycemia
- •Clinical Trials of Intensive Treatment of Glycemia
- •Diabetes Control and Complications Trial
- •The United Kingdom Diabetes Prospective Study (UKPDS)
- •Hypertension
- •Lipids
- •Subclinical and Clinical Diabetic Nephropathy
- •Microalbuminuria and Diabetic Retinopathy
- •Gross Proteinuria and Retinopathy
- •Diabetic Retinopathy as a Risk Indicator of Subclinical Nephropathy
- •Other Risk Factors For Retinopathy
- •Smoking and Drinking
- •Body Mass Index and Physical Activity
- •Hormone and Reproductive Exposures in Women
- •Prevalence and Incidence of Visual Impairment
- •Conclusions
- •Acknowledgments
- •References
- •Introduction
- •Fluorescein Angiography
- •Properties
- •Side Effects
- •Normal Fluorescein Angiography
- •Terminology
- •Fluorescein Angiography in the Evaluation of Diabetic Retinopathy
- •Fluorescein Angiography in the Evaluation of Diabetic Macular Edema
- •Optical Coherence Tomography
- •Low-Coherence Interferometry
- •OCT Image Interpretation
- •OCT Technology Development
- •The Role of OCT in Diabetic Macular Edema
- •Morphologic Patterns of Diabetic Macular Edema
- •Clinical Applications of OCT in Diabetic Macular Edema
- •Conclusions
- •References
- •Diabetic primates
- •Type of Diabetes
- •Histopathology and Rate of Development of the Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic dogs
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic cats
- •Type of Diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Therapies Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic rats
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neuronal disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Diabetic mice
- •Type of Diabetes
- •Type 1 diabetes
- •Type 2 diabetes
- •Histopathology and Rate of Development of Retinopathy
- •Vascular disease
- •Neural disease
- •Therapies or Gene Modifications Studied in this Model
- •Advantages and Disadvantages of the Model
- •Other Rodents
- •Galactose Feeding
- •Nondiabetic Models in Which Growth Factors are Altered
- •VEGF overexpression
- •IGF overexpression
- •PDGF-B-deficient mice
- •Oxygen-Induced Retinopathy
- •Sympathectomy
- •Retinal Ischemia–Reperfusion
- •Summary
- •References
- •Introduction
- •Biochemistry and Genetics of The Polyol Pathway
- •Aldose Reductase
- •The Aldose Reductase Enzyme
- •The Aldose Reductase Gene
- •Polymorphisms of the AR Gene
- •Sorbitol Dehydrogenase
- •The Sorbitol Dehydrogenase Enzyme
- •The Sorbitol Dehydrogenase Gene
- •Ar Polymorphisms and Risk of Diabetic Retinopathy
- •Sdh Polymorphisms and Diabetic Retinopathy
- •Ar Overexpression
- •Sdh Overexpression
- •Ar “Knockout” Mice
- •Sdh-Deficient Mice
- •Osmotic Stress
- •Oxidative Stress
- •Activation of Protein Kinase C
- •Generation of AGE Precursors
- •Proinflammatory Events and Apoptosis
- •Ari Structures and Properties
- •Effects of Aris in Experimental Diabetic Retinopathy
- •The Polyol Pathway in Human Diabetic Retinopathy
- •The Sorbinil Trial
- •Perspective and Needs
- •Rationale for Defining the Pathogenic Role of the Polyol Pathway
- •Needs to be Met to Arrive at Anti-Polyol Pathway Therapy
- •References
- •Introduction to Diabetic Retinopathy
- •Biochemistry of Age Formation
- •Pathogenic Role of Ages In Diabetic Retinopathy
- •AGEs and Clinical Correlation of Diabetic Retinopathy
- •AGE Accumulation in the Eye
- •Effect of AGEs on Retinal Cells
- •RAGE in Diabetic Retinopathy
- •Other AGE Receptors in Diabetic Retinopathy
- •Anti-Age Strategies For Diabetic Retinopathy
- •Conclusion
- •References
- •Introduction
- •Dag-Pkc Pathway
- •Diabetes and Retinal Blood Flow
- •Basement Membrane and Ecm Changes
- •Vascular Permeability and Angiogenesis
- •Conclusions
- •References
- •Sources of Oxidative Stress in The Diabetic Retina
- •Overview
- •Mitochondrial Electron Transport Chain (ETC)
- •Advanced Glycation End (AGE) Product Formation
- •Cyclo-oxygenase (COX)
- •Flux Through Aldose Reductase (AR) Pathway
- •Activation of Protein Kinase C (PKC)
- •Endothelial NO Synthase (eNOS)
- •Inducible NOS (iNOS)
- •NADPH Oxidase
- •Antioxidants in Diabetic Retinopathy
- •Overview
- •Glutathione (GSH)
- •Superoxide Dismutase (SOD)
- •Catalase
- •Effects of Oxidative Stress in The Diabetic Retina
- •Overview
- •Growth Factors and Cytokines
- •Cytoxicity
- •Therapeutic Strategies For Reducing Oxidative Stress
- •Overview
- •Antioxidants
- •PKC Inhibitors
- •Inhibitors of the Renin-Angiotensin System
- •Inhibitors of the Polyol Pathway
- •HMG-CoA Reductase Inhibitors (Statins)
- •PEDF
- •Cannabinoids
- •Cyclo-oxygenase-2 (COX-2) Inhibitors
- •References
- •Pericyte Loss in the Diabetic Retina
- •Introduction
- •Origin and Differentiation
- •Morphology and Distribution
- •Identification
- •Function
- •Contractility
- •Role in Vessel Formation and Stabilization
- •Loss In Diabetic Retinopathy
- •Rats
- •Mice
- •Chinese Hamster
- •Animal Models Mimicking Retinal Pericyte Loss
- •Pdgf-B-Pdgf-Ssr
- •Angiopoietin-Tie
- •Vegf-Vegfr2
- •Mechanisms of Loss
- •Biochemical Pathways
- •Aldose Reductase
- •Age Formation
- •Modification of Ldl
- •Loss Through Active Elimination
- •Capillary Dropout in Diabetic Retinopathy
- •Diabetic Retinopathy
- •Methods to Measure and Detect Capillary Dropout
- •Models to Study Retinal Capillary Dropout in Diabetes
- •Potential Mechanisms For Capillary Dropout
- •Capillary Cell Apoptosis
- •Proinflammatory Changes/Leukostasis
- •Microthrombosis/Platelet Aggregation
- •Consequences of Capillary Dropout
- •Macular Ischemia
- •Neovascularization
- •Macular Edema
- •Acknowledgments
- •References
- •Neuroglial Dysfunction in Diabetic Retinopathy
- •The Neurons of The Retina
- •The Glial Cells of The Retina
- •Diabetes Reduces Retinal Function
- •Diabetes Induces Neurodegeneration in The Retina
- •Neuroinflammation in Diabetic Retinopathy
- •Historical Perspective on Diabetic Retinopathy
- •Neuroglial Dysfunction in Diabetic Retinopathy.
- •References
- •Introduction
- •Inflammatory Cells Promote and Regulate The Development of Ischemic Ocular Neovascularization
- •VEGF as a Proinflammatory Factor in Diabetic Retinopathy
- •VEGF164/165 as a Proinflammatory Cytokine
- •Nonsteroidal Anti-inflammatory Drugs (NSAIDs)
- •Corticosteroids
- •Anti-VEGF Agents
- •Pegaptanib
- •Ranibizumab and Bevacizumab
- •Conclusions
- •Acknowledgment
- •References
- •Glia-Endothelial Interaction
- •Specialized Retinal Vessels Control Flux into Neural Tissue
- •Overview of Tight Junction Proteins
- •Claudins Confer Tight Junction Barrier Properties
- •Occludin Regulates Barrier Properties
- •Alterations in Occludin in Diabetic Retinopathy
- •Ve-Cadherin and Diabetic Retinopathy
- •Permeability in Diabetic Retinopathy
- •Summary and Conclusions
- •References
- •Introduction
- •Stages of Angiogenesis
- •Vascular Endothelial Growth Factor
- •Regulation of Vegf Expression in The Retina
- •Regulation of VEGF in Proliferative Diabetic Retinopathy
- •Regulation of VEGF in Nonproliferative Diabetic Retinopathy
- •Basic Vegf Biology
- •Receptors
- •Vegf’S Multiple Actions on Retinal Endothelial Cells
- •Main Signaling Pathways
- •Other Actions of Vegf
- •Proinflammatory Effects of VEGF
- •VEGF and Retinal Neuronal Development
- •VEGF and Neuroprotection
- •Modulation of Vegf Action By Other Growth Factors
- •Conclusion
- •References
- •Insulin-Like Growth Factor
- •Basic Fibroblast Growth Factor
- •Angiopoietin
- •Erythropoietin
- •Hepatocyte Growth Factor
- •Tumor Necrosis Factor
- •Extracellular Proteinases
- •The Urokinase Plasminogen Activator System (uPA/uPAR System)
- •Proteinases in Retinal Neovascularization
- •Integrins
- •Endogenous Inhibitors of Neovascularization
- •Pigment Epithelium Derived Growth Factor
- •Angiostatin and Endostatin
- •Thrombospondin-1
- •Tissue Inhibitor of Matrix Metalloproteinases
- •Clinical Implications
- •Acknowledgments
- •References
- •Introduction
- •Pathogenesis
- •Vascular Endothelial Growth Factor (Vegf)
- •Vegf in Physiological and Pathological Angiogenesis
- •Vegf in Ocular Neovascularization
- •Vegf and Diabetic Retinopathy
- •Clinical Application of Anti-VEGF Drugs
- •Pegaptanib
- •Bevacizumab
- •Ranibizumab
- •Use of Anti-VEGF Therapies in Diabetic Retinopathy
- •Safety
- •Clinical Experience with Bevacizumab in Diabetic Retinopathy
- •Ranibizumab in Diabetic Macular Edema
- •Effect on Foveal Thickness and Macular Volume
- •Effect on Visual Acuity
- •Summary
- •References
- •Introduction
- •Pkc Inhibition With Ruboxistaurin
- •Early Clinical Trials With Rbx
- •Rbx and Progression of Diabetic Retinopathy
- •Ongoing Trials With Rbx
- •Rbx and Other, Nonocular Complications of Diabetes
- •Safety Profile of Rbx
- •Clinical Status of Rbx
- •Conclusions
- •References
- •The Role of Intravitreal Steroids in the Management of Diabetic Retinopathy
- •Clinical Efficacy
- •Safety
- •Pharmacology
- •Pharmacokinetics
- •Combination With Laser Treatment
- •Clinical Guidelines
- •Macular Edema Caused by Focal Parafoveal Leak
- •Widespread Heavy Diffuse Leak
- •Macular Edema and High-Risk Proliferative Retinopathy
- •Macular Edema Prior to Cataract Surgery
- •Juxtafoveal Hard Exudate With Heavy Leak
- •Control of Systemic Risk Factors
- •The Future of Intravitreal Steroid Therapy
- •References
- •Overview
- •Introduction and Historical Perspective
- •Growth Hormone and Diabetic Retinopathy
- •The IGF-1 System and Retinopathy
- •The Role of SST in Diabetic Retinopathy
- •Rationale for the Clinical use of Octreotide
- •Clinical evidence for sst as a therapeutic for pdr
- •Potential Reasons for Mixed Success in Clinical Trials
- •Future Direction: Sst Analogs in Combination Therapy
- •Conclusion
- •Acknowledgements
- •Introduction
- •Diabetic Retinopathy and Mortality
- •Diabetic Retinopathy and Cerebrovascular Disease
- •Diabetic Retinopathy and Heart Disease
- •Diabetic Retinopathy, Nephropathy, and Neuropathy
- •Conclusion
- •References
- •Name Index
12 Neuroglial Dysfunction in Diabetic
Retinopathy
Heather D. VanGuilder, Thomas W. Gardner,
and Alistair J. Barber
CONTENTS
THE RETINA IS A MULTICELLULAR PHOTON SENSOR
AND PHOTOMULTIPLIER
THE NEURONS OF THE RETINA
THE GLIAL CELLS OF THE RETINA
DIABETES REDUCES RETINAL FUNCTION
DIABETES INDUCES NEURODEGENERATION IN THE RETINA
DIABETES ALTERS THE FUNCTION OF GLIAL
CELLS IN THE RETINA
NEUROINFLAMMATION IN DIABETIC RETINOPATHY
HISTORICAL PERSPECTIVE ON DIABETIC RETINOPATHY
NEUROGLIAL DYSFUNCTION IN DIABETIC RETINOPATHY
REFERENCES
ABSTRACT
Diabetic retinopathy is a vision-threatening disease that impacts many, if not all the different types of cells in the retina. This chapter reviews evidence that the dysfunction of the neuroglial cells of the retina contributes to the pathology of diabetic retinopathy. The basic histology of the neurons and glial cells of the retina is summarized, along with a discussion of the functions of these different cell types, and how they operate collectively to mediate vision. Then the effect of diabetes on retinal function is summarized, along with a discussion of how neurodegeneration, glial dysfunction, and neuroinflammation each may play a part in loss of vision. Finally, the history of research on neuroglial dysfunction in diabetic retinopathy is summarized in order to appreciate the evolution of the notion that vision loss is mediated through abnormalities in neuroglial cells.
From: Contemporary Diabetes: Diabetic Retinopathy
Edited by: E. Duh © Humana Press, Totowa, NJ
283
284 |
VanGuilder et al. |
Key Words: Retina; Neuron; Retinal ganglion cell; Microglia; Macroglia; Astrocyte; Müller cell; Neurodegeneration; Visual function; Electroretinogram.
THE RETINA IS A MULTICELLULAR PHOTON
SENSOR AND PHOTOMULTIPLIER
The retina is a unique component of the central nervous system (CNS), containing a variety of neurons and glial cells. This elegant and complex structure converts visual stimuli into chemical and electrical signals that are transmitted to the brain via the optic nerve. Clinicians and neuroscientists view the retina from distinct perspectives, and both disciplines provide instructive lessons about retinal composition and function. Clinicians view the fundus of the retina as the sum of the visible structures – retinal blood vessels, pigment epithelium, choroid and, to some extent, the vitreous humor. By contrast, neuroscientists concentrate on the cellular organization that is largely invisible to clinicians. This brief overview of retinal structure and function emphasizes the critical role of the invisible neurosensory retina in normal vision, to illustrate how these characteristics may predispose it to compromise the metabolic stresses of diabetes. These relationships are essential to the interpretation of the clinical features of diabetic retinopathy and the processes that disrupt vision.
The cellular anatomy of the mammalian retina was revealed in great detail by Ramón y Cajal more than 100 years ago, when he defined the neuronal subclasses as well as the Müller cells and astrocytes, using Golgi silver staining methods. He recognized the laminar structure of the retina and the fact that neurons comprise the majority of retinal cells. This structure, highly conserved throughout vertebrate evolution from fish to humans, is comprised of three layers of neurons and two layers of synapses, which are minute structures that facilitate interneuronal communication through the release of, and response to, chemical transmitter substances (1).
The neurons are categorized as follows:
First-order: photoreceptors, which produce a neurochemical response to photons Second-order: bipolar, horizontal, and amacrine (“without axons”) cells, which conduct
and regulate signals from photoreceptors
Third-order: ganglion cells, which collect and integrate information from second-order neurons that are organized into opposing on/off receptive fields and transmit electrical impulses via axons which terminate primarily in the lateral geniculate body of the thalamus.
THE NEURONS OF THE RETINA
The histological configuration of the retina implies that communication between neurons can be broken down into at least three distinct stages. Retinal neurons are organized in three layers separated by two plexuses of densely packed synaptic connections that enable different types of neurons to communicate with each other. The two layers of synapses (plexiform layers) mediate signal transduction from the photoreceptors (firstorder neurons) through bipolar interneurons (second-order neurons) to the ganglion cells (third-order neurons). The axons of the retinal ganglion cells cofasciculate to form
Neuroglial Dysfunction in Diabetic Retinopathy |
285 |
the optic nerve, which transmits integrated visual signals to be interpreted by the occipital cortex.
Photoreceptors are organized with their cell bodies (inner segments) in the outer nuclear layer and the stacked discs (outer segments), which contain photon-detecting photopigments, (rhodopsin and opsins), in the photoreceptor layer, with a thin cilium connecting the two layers. Photoreceptors number approximately 126 million in young adult human retinas, a factor of 10 more than the ganglion cells (2), thus reflecting the high degree of signal integration within the retina. Photoreceptors synapse with rod ON (light-stimulated) bipolar cells and cone photoreceptors synapse with ON and OFF (light-inhibited) bipolar cells. The ON and OFF bipolar cells synapse, in turn, with ON and OFF ganglion cells, respectively (Fig. 1). In this manner, second-order neurons integrate signals from groups of adjacent photoreceptors, and in concert with third-order neurons, ganglion cells, provide the center-surround receptive fields that lead to the ability to detect contrast and motion (3).
Fig. 1. Organization of retinal neurons. Neurons of the retina are organized into three distinct layers of cell bodies (nuclear layers), separated by two layers of densely packed synapses (plexiform layers). Light passes through the entire retina to the photoreceptors, which transduce visual signals into chemical signals that are transmitted vertically through bipolar cells to the ganglion cells. These signals are modulated by two stages of horizontal signal processing mediated by the horizontal and amacrine cells. POS photoreceptor outer segments; ONL outer nuclear layer; OPL outer plexiform layer; INL inner nuclear layer; IPL inner plexiform layer; GCL ganglion cell layer; NFL nerve fiber layer.
286 |
VanGuilder et al. |
The photoreceptors absorb photons of light and begin a cascade of signal transduction. Rod photoreceptors are extremely sensitive to light, and maintain vision in low illumination (scotopic conditions), while cone photoreceptors mediate color vision in bright light (photopic conditions), and afford a high degree of visual acuity. The primate retina contains a fovea, which has a high concentration of cone photoreceptors to augment acuity. Signals are transmitted from photoreceptors by synaptic connections in the outer plexiform layer to bipolar cells and horizontal cells. Horizontal cells provide modulatory input to photoreceptor terminals, and also perform pan-retinal signal averaging through a network of inter-horizontal gap junctions to refine visual information. Bipolar cells, subtypes of which selectively connect with rod or cone photoreceptors, transmit signals from the photoreceptors to the ganglion cells, while amacrine cells refine both bipolar and ganglion cell output. Together, these vertical and lateral interactions allow the retina to function over a wide dynamic range.
Synaptic communication in the retina is mediated by a variety of neurotransmitters. Photoreceptors and bipolar cells release the excitatory neurotransmitter, glutamate, while horizontal and amacrine cells release the inhibitory neurotransmitter, gammaaminobutyric acid (GABA). In addition, neurotransmitters, including dopamine, acetylcholine, and norepinephrine, are also involved in neurotransmission. Glutamate and GABA, however, are the predominant signaling molecules and contribute to synaptic communication among almost all retinal neurons. These substances act on neurons to generate an intraneuronal electrical potential that subsequently results in the release of chemical neurotransmitters from the receiving cell, enabling transduction of visual information through multiple types of retinal neurons. In the complex signal processing pathway of the retina, the outer plexiform layer (OPL) contains connections between photoreceptors, horizontal cells, and bipolar cells, while the inner plexiform layer (IPL) comprises connections between the bipolar, amacrine, and ganglion cells. Each plexiform layer achieves one step in the vertical transmission of visual signals through the retina, as well as additional horizontal signal modification mediated by horizontal and amacrine cells, which sharpen signals by emphasizing pertinent information, while minimizing interference and extraneous noise. Although a high degree of redundancy may preserve basic neurotransmission in many pathological states, each neuronal subtype fulfills a specific and fundamental role in signal processing that is critical to various aspects of normal vision. The functional aspects of various retinal neurons, such as the constitutively active dark current of the photoreceptors and the necessity for ganglion cells to maintain large, complex dendritic branches, impose a tremendous metabolic requirement that the limited retinal vasculature and retinal pigment epithelium must meet without interfering with the phototransduction by the photoreceptor outer segments. To meet this requirement, retinal neurons rely heavily on effective vascular and supporting glial cell function for waste removal and trophic support (4–8).
THE GLIAL CELLS OF THE RETINA
The glial cells of the retina form three main populations: astrocytes, Müller cells, and microglia (Fig. 2). Astrocytes originate in the optic nerve and migrate into the maturing retina to form a monolayer apposed to the inner limiting membrane, where they interact with neurons and vascular cells (7, 9), and contribute to the maintenance of the inner
Neuroglial Dysfunction in Diabetic Retinopathy |
287 |
Fig. 2. Localization of retinal glia. Glial cells are differentially distributed throughout the neural retina. Müller cells are large radial glia that span the entire thickness of the retina, with endfeet contacting the inner limiting membrane and microvilli projecting through the outer limiting membrane to the subretinal space. Astrocytes are located primarily in the inner retina along the nerve fiber layer, where they appose the inner limiting membrane. Microglia reside in the inner retina, typically in the inner plexiform layer/ganglion cell layer and inner plexiform layer/inner nuclear layer interfaces.
part of the blood–retina barrier (10). Müller cells are unique radial glia cells that closely interact with retinal neurons, providing nutritional support and regulating neuronal microenvironments by removing GABA and glutamate from synapses (6). Microglia are monocyte-derived cells with immunological functions in the immuno-privileged CNS. As such, microglial activation is implicated in retinal immune responses that often contribute to neurodegeneration and inflammation. These cells produce inflammatory cytokines, but also provide neuroprotective substances that aid in the support of neuronal and vascular cells (11). Together, these three types of glial cells support and influence neuronal and vascular function. Healthy functioning of glial and vascular cells is required to provide nutrients, waste disposal and trophic support to the neural retina, but it is the neurons and glia themselves that induce and maintain the vascular phenotype optimal for their own survival. Gross pathological abnormalities have been identified in retinal vasculature with diabetes, including pericyte ghosts, acellular capillaries, leukostasis, and tight junction breakdown, all of which have the potential to contribute to vascular leakage and nonperfusion (12–14). These events may induce glial-cell changes, such as astrocyte and Müller-cell reactivity and microglial activation, which can further exacerbate vascular dysfunction through the release of cytokines and vascular endothelial
